Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Next Previous
Trial Profile

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epcoritamab (Primary) ; Anakinra; Bendamustine; Buclizine; Gemcitabine; Oxaliplatin; Rituximab; Tocilizumab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EPCORE DLBCL-1; EPCORE&TRADE
  • Sponsors Genmab

Most Recent Events

  • 03 Nov 2025 According to Genmab media release, data from the study will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9.
  • 10 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
  • 23 Jul 2024 According to an AbbVie media release, EPKINLY has also received a positive recommendation for the same indication from INESSS to list it in Quebec contingent on submission and reassessment of phase III clinical data once available.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top